During this highly interactive session, panelists will lead the audience through the evaluation, differential diagnosis, and treatment for a nuanced case of myositis. For the first time, panelists will integrate artificial intelligence in the form of ChatGPT into the process, said moderator Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS.

In Monday’s plenary session, researchers will discuss new developments related to CXCL13+ peripheral helper cells, SGLT2 inhibitor use in patients with lupus, benefits of microbiome transplantation in osteoarthritis, respiratory outcomes in rheumatoid arthritis and interstitial lung disease, split-dosing in rheumatoid arthritis, and the effects of prophylaxis on infections during treatment of granulomatosis with polyangiitis.

Jane Buckner, MD, will discuss the efficacy and limitations of various therapies to manipulate immune response that targets the pathogenic processes and affected organs in autoimmunity while sparing the remainder of the immune response. Antigen-specific therapy provides potential for precision medicine without deleterious effects on patients, but according to Dr. Buckner, researchers must first answer…

Special considerations for vaccination in individuals living with rheumatic diseases have been the subject of several guidelines from medical societies in recent years, such as the ACR’s 2022 Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Kathryn Edwards, MD, will discuss the safety and immunogenicity of pediatric vaccines.

Nehad Soloman, MD, FACR, will help fellow rheumatologists understand their value in the job market, the factors that influence that value, and how to leverage it all when negotiating a contract. The session also will include a legal primer related to compensation and negotiation.

Jayasree K. Iyer, PhD, MSc, CEO of the Access to Medicine Foundation, opened the Global Summit and highlighted the unmet pharmacological needs of a significant portion of the world’s population. In many parts of the world, access to drugs to treat rheumatic diseases, in particular, is a low priority compared to access to drugs for…

In the first of three plenary sessions, researchers will discuss new developments in rheumatic disease and pregnancy, the pathogenesis of systemic lupus erythematous-associated pulmonary arterial hypertension, sexually dimorphic gene expression of synovial macrophages in rheumatoid arthritis, therapy for severe granulomatosis with polyangiitis and microscopic polyangiitis, and consensus recommendations for musculoskeletal ultrasound education.

Cornelia M. Weyand, MD, PhD, will explain how the bioenergetic stress experienced by the immune system of a person living with rheumatoid arthritis causes their immune cells to malfunction. For the past 50 years, providers have traditionally suppressed patients’ immune systems with inhibitors to eliminate cell proliferation, which reduces inflammation. Dr. Weyand believes this strategy…

Attendees will learn concepts and terminology related to LGBTQIA+ identities, as well as the effects of stigma, minority stress, and health disparities experienced by these individuals in the healthcare setting. “We want everyone that comes through our hospital or clinic to feel welcome,” said Cameron Nicholson, PA-C.

Researchers are just beginning to piece together the roles of various environmental perturbations on osteoarthritis (OA). Matlock Jeffries, MD, will discuss the articular microbiome in OA, including its potential role in OA pathogenesis, as part of a panel on microbiome niches.